4-(1,2-Dihydroxyethyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1,2-Dihydroxyethyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid
• 英文别名: 4-(1,2-dihydroxyethyl)-4-(hydroxymethyl)piperidine-1-carboxylic acid
• 化学式: C₉H₁₇NO₅
• 分子量: 219.23
• InChiKey: URLUVAKRUHKMBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  101
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：SHANGHAI BLUERAY BIOPHARMA CO., LTD.

  公开号：US20210053989A1

  公开（公告）日：2021-02-25

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
• PYRIMIDINE-4(3H)-KETONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE AND PHARMACOLOGY
  申请人：Beijing InnoCare Pharma Tech Co., Ltd.

  公开号：EP4092024A1

  公开（公告）日：2022-11-23

  The present invention relates to pyrimidin-4(3H)-one heterocyclic compounds for inhibiting or regulating SHP2, preparation methods thereof, and pharmaceutical use thereof. Specifically, the present invention relates to compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof, a method of applying the compounds or pharmaceutically acceptable salts thereof for treating and/or preventing SHP2-mediated diseases, particularly cancers, and preparation methods for the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to use of the compounds or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating and/or preventing SHP2-mediated diseases. Herein, all substituents in the general formula (I) are as defined in the description.

  本发明涉及用于抑制或调节SHP2的嘧啶-4(3H)-酮杂环化合物、其制备方法及其药物用途。具体地说，本发明涉及通式(I)代表的化合物及其药学上可接受的盐、含有该化合物或其药学上可接受的盐的药物组合物、应用该化合物或其药学上可接受的盐治疗和/或预防SHP2介导的疾病，特别是癌症的方法，以及该化合物或其药学上可接受的盐的制备方法。本发明进一步涉及本发明化合物或其药学上可接受的盐或含有本发明化合物或其药学上可接受的盐的药物组合物在制备治疗和/或预防SHP2介导的疾病的药物中的用途。在此，通式（I）中的所有取代基均如描述中所定义。
• Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
  申请人：BLUERAY THERAPEUTICS (SHANGHAI) CO., LTD.

  公开号：US11498930B2

  公开（公告）日：2022-11-15

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开披露了一种嘧啶融合环状化合物或其药学上可接受的盐、水合物、原药、立体异构体、溶解物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备预防和/或治疗与 SHP2 活性异常相关的疾病或病症的药物的用途。
• [EN] PYRIMIDINE-4(3H)-KETONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE AND PHARMACOLOGY<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE DE PYRIMIDINE-4(3H)-CÉTONE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION EN MÉDECINE ET EN PHARMACOLOGIE<br/>[ZH] 嘧啶-4(3H)-酮类杂环化合物、其制备方法及其在医药学上的应用
  申请人：BEIJING INNOCARE PHARMA TECH CO LTD

  公开号：WO2021143701A1

  公开（公告）日：2021-07-22

  本发明涉及适用于抑制或调控SHP2的嘧啶-4(3H)-酮类杂环化合物、其制备方法及其在医药学上的应用。具体而言，本发明涉及一种通式(I)所示的化合物及其可药用的盐、含有所述化合物或其可药用的盐的药物组合物、应用所述化合物或其可药用的盐治疗和/或预防由SHP2介导的相关病症、特别是癌症的方法以及所述化合物或其可药用的盐的制备方法。本发明还涉及所述化合物或其可药用的盐或含有所述化合物或其可药用的盐的药物组合物在制备用于治疗和/或预防SHP2介导的相关病症的药物中的用途。其中通式(I)的各取代基与说明书中的定义相同。